NYSE:LH (USA) Also trade in: Germany Mexico UK

Laboratory Corp of America Holdings

$ 167.46 1.09 (0.66%)
Volume: 587,936 Avg Vol (1m): 858,414
Market Cap $: 16.49 Bil Enterprise Value $: 22.14 Bil
P/E (TTM): 19.05 P/B: 2.32
Earnings Power Value 54.11
Net Current Asset Value -70.09
Tangible Book -41.8
Projected FCF 167.7
Median P/S Value 175.41
Graham Number 0
Peter Lynch Value 86.32
DCF (FCF Based) 93.51
DCF (Earnings Based) 107.53
1Y (-%)

Financial Strength : 5/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.06
Cash-To-Debt ranked lower than
96.55% of 261 companies
in the Diagnostics & Research industry.
Industry Max: 32990, Med: 3.52, Min: 0.01
LH: 0.06
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.02, Med: 0.08, Max: 10000
Current: 0.06
0.02
10000
Equity-to-Asset 0.42
Equity-to-Asset ranked lower than
77.41% of 239 companies
in the Diagnostics & Research industry.
Industry Max: 0.97, Med: 0.61, Min: -2.81
LH: 0.42
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.14, Med: 0.42, Max: 0.91
Current: 0.42
0.14
0.91
Debt-to-Equity 0.84
Debt-to-Equity ranked lower than
79.88% of 164 companies
in the Diagnostics & Research industry.
Industry Max: 22.86, Med: 0.36, Min: 0.01
LH: 0.84
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: 0.05, Med: 0.89, Max: 4.96
Current: 0.84
0.05
4.96
Debt-to-EBITDA 2.90
Debt-to-EBITDA ranked lower than
73.28% of 116 companies
in the Diagnostics & Research industry.
Industry Max: 77.72, Med: 1.77, Min: 0.03
LH: 2.9
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: 1.22, Med: 2.5, Max: 4.36
Current: 2.9
1.22
4.36
Interest Coverage 5.87
Interest Coverage ranked lower than
76.07% of 163 companies
in the Diagnostics & Research industry.
Industry Max: 15605.52, Med: 76.01, Min: 0.54
LH: 5.87
Ranked among companies with meaningful Interest Coverage only.
Interest Coverage range over the past 10 years
Min: 4.04, Med: 9.46, Max: 15.09
Current: 5.87
4.04
15.09
Piotroski F-Score 5
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 2.58
DISTRESS
GREY
SAFE
Beneish M-Score -2.59
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 7.52%
WACC 8.01%

Profitability & Growth : 8/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 12.35
Operating Margin ranked higher than
75.62% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 53.36, Med: -0.59, Min: -70300
LH: 12.35
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: 12.12, Med: 16.39, Max: 20.22
Current: 12.35
12.12
20.22
Net Margin % 7.95
Net Margin ranked higher than
84.23% of 241 companies
in the Diagnostics & Research industry.
Industry Max: 41.13, Med: -2.48, Min: -119600
LH: 7.95
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: 5.04, Med: 9.63, Max: 11.9
Current: 7.95
5.04
11.9
ROE % 12.67
ROE ranked higher than
91.32% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 61.7, Med: -6.75, Min: -12038.19
LH: 12.67
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: 11.27, Med: 20.43, Max: 28.64
Current: 12.67
11.27
28.64
ROA % 5.39
ROA ranked higher than
82.82% of 262 companies
in the Diagnostics & Research industry.
Industry Max: 1174.65, Med: -4.54, Min: -1248.4
LH: 5.39
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: 4.09, Med: 8.14, Max: 11.43
Current: 5.39
4.09
11.43
ROC (Joel Greenblatt) % 67.22
ROC (Joel Greenblatt) ranked higher than
86.49% of 259 companies
in the Diagnostics & Research industry.
Industry Max: 17601.65, Med: -9.57, Min: -3842027.78
LH: 67.22
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: 57.27, Med: 86.84, Max: 138.05
Current: 67.22
57.27
138.05
3-Year Total Revenue Growth Rate 9.30
3-Year Revenue Growth Rate ranked higher than
69.23% of 182 companies
in the Diagnostics & Research industry.
Industry Max: 371, Med: 4.8, Min: -100
LH: 8.6
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -21.4, Med: 10.6, Max: 23.6
Current: 8.6
-21.4
23.6
3-Year Total EBITDA Growth Rate 12.30
3-Year EBITDA Growth Rate ranked higher than
51.12% of 178 companies
in the Diagnostics & Research industry.
Industry Max: 141.7, Med: 10.1, Min: -340.1
LH: 11.5
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -57, Med: 8.3, Max: 157.1
Current: 11.5
-57
157.1
3-Year EPS w/o NRI Growth Rate 25.60
3-Year EPS w/o NRI Growth Rate ranked higher than
74.23% of 163 companies
in the Diagnostics & Research industry.
Industry Max: 138.7, Med: 10.1, Min: -301
LH: 25.6
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: 7.1, Max: 82.8
Current: 25.6
0
82.8

» LH's 30-Y Financials

Financials (Next Earnings Date: 2019-07-25)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NYSE:LH

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Medical Diagnostics & Research » Diagnostics & Research    NAICS : 621511    SIC : 8071
Compare SHSE:603259 NYSE:WAT NYSE:DGX NAS:EXAS NYSE:MTD TSE:6869 XTER:SRT3 NAS:DXCM NAS:IDXX NYSE:PKI XPAR:BIM NYSE:BIO NYSE:QGEN XSWX:LONN XPAR:ERF NAS:ICLR NYSE:CRL NAS:PRAH NAS:BRKR NYSE:A
Traded in other countries LAB.Germany 0JSY.UK
Address 358 South Main Street, Burlington, NC, USA, 27215
Laboratory Corporation of America is the nation's second- largest independent clinical laboratory, with roughly 20% of the independent lab market. The company operates more than 1,800 patient-service centers, offering a broad range of clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing. With the addition of Covance, LabCorp also has a sizable footprint in the global contract research organization market.

Ratios

Current vs industry vs history
PE Ratio (TTM) 19.05
PE Ratio ranked higher than
87.61% of 113 companies
in the Diagnostics & Research industry.
Industry Max: 1345, Med: 35, Min: 0.33
LH: 19.05
Ranked among companies with meaningful PE Ratio only.
PE Ratio range over the past 10 years
Min: 10.52, Med: 16.55, Max: 28.94
Current: 19.05
10.52
28.94
Forward PE Ratio 14.79
Forward P/E ranked higher than
95.00% of 40 companies
in the Diagnostics & Research industry.
Industry Max: 78.74, Med: 9999, Min: 11.64
LH: 14.79
Ranked among companies with meaningful Forward P/E only.
N/A
PE Ratio without NRI 19.05
PE without NRI ranked higher than
87.61% of 113 companies
in the Diagnostics & Research industry.
Industry Max: 1345, Med: 35.56, Min: 0.34
LH: 19.05
Ranked among companies with meaningful PE without NRI only.
PE without NRI range over the past 10 years
Min: 10.52, Med: 16.55, Max: 28.94
Current: 19.05
10.52
28.94
Price-to-Owner-Earnings 15.95
Price-to-Owner-Earnings ranked higher than
81.58% of 76 companies
in the Diagnostics & Research industry.
Industry Max: 1523.53, Med: 36.75, Min: 4.91
LH: 15.95
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Price-to-Owner-Earnings range over the past 10 years
Min: 9.35, Med: 14.02, Max: 42.34
Current: 15.95
9.35
42.34
PB Ratio 2.32
PB Ratio ranked higher than
71.43% of 245 companies
in the Diagnostics & Research industry.
Industry Max: 270, Med: 4.02, Min: 0.15
LH: 2.32
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 1.8, Med: 3.18, Max: 4.84
Current: 2.32
1.8
4.84
PS Ratio 1.50
PS Ratio ranked higher than
75.65% of 230 companies
in the Diagnostics & Research industry.
Industry Max: 6350, Med: 3.81, Min: 0.07
LH: 1.5
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 1.12, Med: 1.58, Max: 2.03
Current: 1.5
1.12
2.03
Price-to-Free-Cash-Flow 19.16
Price-to-Free-Cash-Flow ranked higher than
83.75% of 80 companies
in the Diagnostics & Research industry.
Industry Max: 1356.19, Med: 29.22, Min: 0.35
LH: 19.16
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Price-to-Free-Cash-Flow range over the past 10 years
Min: 9.14, Med: 14.31, Max: 32.39
Current: 19.16
9.14
32.39
Price-to-Operating-Cash-Flow 13.19
Price-to-Operating-Cash-Flow ranked higher than
80.41% of 97 companies
in the Diagnostics & Research industry.
Industry Max: 1739.7, Med: 19.94, Min: 0.35
LH: 13.19
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 7.46, Med: 11.14, Max: 21.23
Current: 13.19
7.46
21.23
EV-to-EBIT 14.57
EV-to-EBIT ranked higher than
71.19% of 118 companies
in the Diagnostics & Research industry.
Industry Max: 341.21, Med: 25.06, Min: 5.74
LH: 14.57
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: 8.6, Med: 11.8, Max: 21.6
Current: 14.57
8.6
21.6
EV-to-EBITDA 10.72
EV-to-EBITDA ranked higher than
73.48% of 132 companies
in the Diagnostics & Research industry.
Industry Max: 486.47, Med: 20.75, Min: 3.94
LH: 10.72
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: 7.1, Med: 9.5, Max: 16.2
Current: 10.72
7.1
16.2
EV-to-Revenue 1.96
EV-to-Revenue ranked higher than
73.14% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 19679, Med: 4.24, Min: 0.09
LH: 1.96
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 1.6, Med: 2, Max: 2.9
Current: 1.96
1.6
2.9
PEG Ratio 2.15
PEG Ratio ranked higher than
64.58% of 48 companies
in the Diagnostics & Research industry.
Industry Max: 128.13, Med: 3.26, Min: 0.32
LH: 2.15
Ranked among companies with meaningful PEG Ratio only.
PEG Ratio range over the past 10 years
Min: 0.74, Med: 1.79, Max: 6.22
Current: 2.15
0.74
6.22
Shiller PE Ratio 23.47
Shiller PE Ratio ranked higher than
79.49% of 39 companies
in the Diagnostics & Research industry.
Industry Max: 459.08, Med: 52.49, Min: 10.19
LH: 23.47
Ranked among companies with meaningful Shiller PE Ratio only.
Shiller PE Ratio range over the past 10 years
Min: 17.86, Med: 23.42, Max: 31.04
Current: 23.47
17.86
31.04
Current Ratio 1.14
Current Ratio ranked lower than
79.60% of 250 companies
in the Diagnostics & Research industry.
Industry Max: 97.84, Med: 2.58, Min: 0.02
LH: 1.14
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.47, Med: 1.57, Max: 4.38
Current: 1.14
0.47
4.38
Quick Ratio 1.05
Quick Ratio ranked lower than
74.40% of 250 companies
in the Diagnostics & Research industry.
Industry Max: 97.84, Med: 2.14, Min: 0.02
LH: 1.05
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.44, Med: 1.48, Max: 4.38
Current: 1.05
0.44
4.38
Days Inventory 10.48
Days Inventory ranked higher than
89.71% of 204 companies
in the Diagnostics & Research industry.
Industry Max: 917.88, Med: 79.76, Min: 0.37
LH: 10.48
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 10.39, Med: 12.05, Max: 13.23
Current: 10.48
10.39
13.23
Days Sales Outstanding 50.59
Days Sales Outstanding ranked higher than
66.67% of 204 companies
in the Diagnostics & Research industry.
Industry Max: 521.64, Med: 67.51, Min: 1
LH: 50.59
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 44.64, Med: 48.57, Max: 54.21
Current: 50.59
44.64
54.21
Days Payable 26.72
Days Payable ranked lower than
78.07% of 187 companies
in the Diagnostics & Research industry.
Industry Max: 981.81, Med: 63.34, Min: 1
LH: 26.72
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 24.54, Med: 28.6, Max: 32.38
Current: 26.72
24.54
32.38

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate 0.10
3-Year Share Buyback Rate ranked higher than
57.78% of 180 companies
in the Diagnostics & Research industry.
Industry Max: 3.4, Med: -7.9, Min: -1732.6
LH: 0.1
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -42.1, Med: 1.2, Max: 6.6
Current: 0.1
-42.1
6.6

Valuation & Return

Current vs industry vs history
Price-to-Projected-FCF 1.00
Price-to-Intrinsic-Value-Projected-FCF ranked higher than
86.67% of 75 companies
in the Diagnostics & Research industry.
Industry Max: 449, Med: 2.41, Min: 0.47
LH: 1
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 0.56, Med: 1.06, Max: 4.87
Current: 1
0.56
4.87
Price-to-DCF (Earnings Based) 1.56
Price-to-Intrinsic-Value-DCF (Earnings Based) ranked higher than
88.24% of 17 companies
in the Diagnostics & Research industry.
Industry Max: 6.59, Med: 1.86, Min: 0.72
LH: 1.56
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
Price-to-Intrinsic-Value-DCF (Earnings Based) range over the past 10 years
Min: 0.75, Med: 1.15, Max: 2.44
Current: 1.56
0.75
2.44
Price-to-Median-PS-Value 0.95
Price-to-Median-PS-Value ranked lower than
54.40% of 193 companies
in the Diagnostics & Research industry.
Industry Max: 7.22, Med: 1.01, Min: 0.01
LH: 0.95
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.07, Med: 1.02, Max: 3.03
Current: 0.95
0.07
3.03
Price-to-Peter-Lynch-Fair-Value 1.94
Price-to-Peter-Lynch-Fair-Value ranked higher than
53.33% of 30 companies
in the Diagnostics & Research industry.
Industry Max: 15.31, Med: 2.01, Min: 0.83
LH: 1.94
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
Price-to-Peter-Lynch-Fair-Value range over the past 10 years
Min: 0.53, Med: 1.62, Max: 7.78
Current: 1.94
0.53
7.78
Earnings Yield (Joel Greenblatt) % 6.85
Earnings Yield (Greenblatt) ranked higher than
87.17% of 265 companies
in the Diagnostics & Research industry.
Industry Max: 17.42, Med: -0.98, Min: -1428.57
LH: 6.85
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: 4.6, Med: 8.5, Max: 11.7
Current: 6.85
4.6
11.7
Forward Rate of Return (Yacktman) % 14.75
Forward Rate of Return ranked higher than
60.00% of 70 companies
in the Diagnostics & Research industry.
Industry Max: 7802.99, Med: 8.45, Min: -35.9
LH: 14.75
Ranked among companies with meaningful Forward Rate of Return only.
Forward Rate of Return range over the past 10 years
Min: 10, Med: 15, Max: 25.2
Current: 14.75
10
25.2

More Statistics

Revenue (TTM) (Mil) $ 11,276.3
EPS (TTM) $ 8.79
Beta 1.23
Volatility % 24.18
52-Week Range $ 119.38 - 190.36
Shares Outstanding (Mil) 98.5

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 5
Positive ROA Y
Positive CFROA Y
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy Y
Higher Gross Margin yoy N
Higher Asset Turnover yoy N